Explore

Trendline Trendline
CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs

CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs

CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs
Trendline Trendline
Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors

Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors

Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors
Trendline Trendline
Exelixis to Announce Q2 2026 Financial Results with Conference Call and Webcast

Exelixis to Announce Q2 2026 Financial Results with Conference Call and Webcast

Exelixis to Announce Q2 2026 Financial Results with Conference Call and Webcast
Trendline Trendline
GSK Secures FDA Approval for Jideytro, Enhancing Lung Cancer Treatment Options

GSK Secures FDA Approval for Jideytro, Enhancing Lung Cancer Treatment Options

GSK Secures FDA Approval for Jideytro, Enhancing Lung Cancer Treatment Options
Trendline Trendline
Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results
Trendline Trendline
Johnson Johnson's Multiple Myeloma Therapies Show Promising Results in Phase 3 Trial

Johnson Johnson's Multiple Myeloma Therapies Show Promising Results in Phase 3 Trial

Johnson Johnson's Multiple Myeloma Therapies Show Promising Results in Phase 3 Trial
Trendline Trendline
Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Trial Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Trial Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Trial Results
Trendline Trendline
BeOne Medicines to Invest $300 Million in Hopewell Campus Expansion

BeOne Medicines to Invest $300 Million in Hopewell Campus Expansion

BeOne Medicines to Invest $300 Million in Hopewell Campus Expansion
Trendline Trendline
Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment

Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment

Summit and Akeso Present Promising Western Data for Ivonescimab in Lung Cancer Treatment
Trendline Trendline
Pheast Therapeutics Reports Anti-Tumor Activity of PHST001 in Cancer Research

Pheast Therapeutics Reports Anti-Tumor Activity of PHST001 in Cancer Research

Pheast Therapeutics Reports Anti-Tumor Activity of PHST001 in Cancer Research
Trendline Trendline
Citius Oncology Expands LYMPHIR's Commercial Reach Across the U.S.

Citius Oncology Expands LYMPHIR's Commercial Reach Across the U.S.

Citius Oncology Expands LYMPHIR's Commercial Reach Across the U.S.
Trendline Trendline
Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials